ClinicalTrials.gg
RecruitingNCT06984679Updated Mar 27, 2026

Physical Impairments in Children With Cystic Fibrosis

An observational study in Cystic Fibrosis (CF) and Cystic Fibrosis in Children, sponsored by Izmir Democracy University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Izmir Democracy University · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
50
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Cystic Fibrosis with a site in Turkey — 4 open to participants now, 4 under way, none of them phase 3. Cystic Fibrosis · Turkey.

Planned enrollment
12th of 27
50 · median 50
Started
2025
with 3 others
Observational
27 of 49
3 open now
Registered
43rd of 49
by date

Among the 49 studies in Cystic Fibrosis with a site in Turkey, this one is the 12th largest by planned enrollment of the 27 observational ones that give a count, is one of 4 that started in 2025, is one of 27 observational ones, and was the 43rd registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 49 studies in Cystic Fibrosis with a site in Turkey are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Cystic Fibrosis with a site in Turkey, or all of them as a file.
02

Study summary

It is aimed to reveal impairments regarding urinary incontinence, dyspnea, muscle strength, functional capacity or quality of life in children and adolescents with cystic fibrosis compared to healthy children and adolescents.

Read the detailed description

This study aims to compare dyspnea, functional capacity, muscle strength, urinary incontinence and quality of life between children and adolescents with cystic fibrosis and healthy children and adolescents. Participants will be assessed for these parameters through clinical evaluations, exercise tests, questionnaires and measurements. The study aims to understand the health implications of cystic fibrosis and provide the basis for improvements in the health management of these individuals.

03

Conditions studied

  • Cystic Fibrosis (CF)
  • Cystic Fibrosis in Children

Keywords

  • Cystic Fibrosis
  • Urinary Incontinence
  • Dyspnea
  • Muscle Strength
  • Quality of Life
  • Exercise Test
04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

At least 25 patients with cystic fibrosis will be included in the main group and at least 25 healthy individuals will be included in the control group.

Eligibility criteria

Inclusion Criteria for Children and Adolescents with Cystic Fibrosis:

  • To be between the ages of 6-18
  • To have been diagnosed with cystic fibrosis
  • To be clinically stable for at least 3 weeks
  • To have the necessary cooperation for the measurements
  • To volunteer to participate in the study

Inclusion Criteria for Healthy Children and Adolescents:

  • To be between the ages of 6-18
  • To be in a similar average and ratio with the group of children and adolescents with cystic fibrosis in terms of age and gender
  • To have the necessary cooperation for the measurements
  • To volunteer to participate in the study

Exclusion Criteria for Children and Adolescents with Cystic Fibrosis:

  • Having any orthopedic, neurological, psychological or cardiovascular problem that may prevent the measurements from being performed in the last 6 months
  • Smoking or quitting smoking

Exclusion Criteria for Healthy Children and Adolescents:

  • Having any orthopedic, neurological, psychological or cardiovascular problem that may prevent the measurements from being performed in the last 6 months
  • Having any chronic disease
  • Smoking or quitting smoking
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cystic Fibrosis Group

    This group will consist of children and adolescents with cystic fibrosis.

    Other: Physical Evaluations in Children with Cystic Fibrosis

  • Control Group

    This group will consist of healthy children and adolescents.

    Other: Physical Evaluations in Healthy Children

Interventions

  • OtherPhysical Evaluations in Children with Cystic Fibrosis

    In this study, dyspnea, functional capacity, muscle strength, urinary incontinence and quality of life will be evaluated in children and adolescents with cystic fibrosis. The data to be obtained through all these evaluations will be done face to face within 45-60 minutes.

  • OtherPhysical Evaluations in Healthy Children

    In this study, dyspnea, functional capacity, muscle strength, urinary incontinence and quality of life will be evaluated in healthy children and adolescents. The data to be obtained from all these assessments will be made face to face within 45-60 minutes.

06

What researchers measure

Primary outcomes

  1. Hand Grip Strength

    Grip strength will be measured using a dynamometer. Each hand will be tested three times, and the highest value will be recorded for both sides.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Dyspnea score

    Dyspnea will be assessed with the Modified Medical Research Council (MMRC) Dyspnea Scale, scored from 0 (no dyspnea) to 4 (maximum severity).

    Time frame: through study completion, an average of 1 year

  2. Pulmonary Function Test Evaluation

    Lung function will be assessed with a spirometer. The highest value of the three measurements will be used and interpreted according to gender, age, weight and height. A value below 80% of the expected value will be interpreted as abnormal.

    Time frame: through study completion, an average of 1 year

  3. Respiratory Muscle Strength Evaluation

    Respiratory muscle strength will be assessed with a spirometer. The test will be conducted with the participant seated, using a mouthpiece and a nose clip. The highest value for inspiratory and expiratory pressure will be recorded. A value below 80% of the expected value will be interpreted as abnormal.

    Time frame: through study completion, an average of 1 year

  4. Cough Strength Evaluation

    The peak cough expiratory flow of the individual will be assessed using a peak flow meter. The best of at least three repetitions is recorded.A value above 450 indicates effective cough.

    Time frame: through study completion, an average of 1 year

  5. Aerobic Exercise Capacity Evaluation

    Aerobic capacity will be assessed twice via 6-minute walk test. The longest distance will be used for analysis. A value below 80% of the expected value will be interpreted as abnormal.

    Time frame: through study completion, an average of 1 year

  6. Anaerobic Exercise Capacity Evaluation

    Anaerobic capacity will be assessed via the 3-minute step test (3-STT). For the 3-STT, participants will rest for 10 minutes before performing the test with a 15 cm step at a rate of 30 steps per minute, controlled by a metronome. The total number of steps will be recorded.A high number of steps indicates good capacity.

    Time frame: through study completion, an average of 1 year

  7. Quality of Life Score

    The scale we will use to assess health-related quality of life, the Pediatric Quality of Life Inventory (PedsQL 4.0). The scale was developed to assess the health-related quality of life of children and adolescents between the ages of 2 and 18 and consists of physical, emotional, social and school functioning items, totaling 23 items.Scores from this questionnaire are converted to a scale of 0 to 100. Higher scores indicate better health-related quality of life.

    Time frame: through study completion, an average of 1 year

  8. Urinary incontinence score

    Urinary incontinence will be assessed using the Voiding Dysfunction Symptom Score, a 15-item questionnaire. A score above 8.5 indicates the presence of lower urinary tract symptoms.

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Tuğay, B. U., Arıkan, H., & Özçelik, U. (2004). Kistik fibrozisli çocuklarda pulmoner fonksiyonlar ve vücut kompozisyonu ile kas kuvveti arasındaki ilişki. Fizyoterapi ve Rehabilitasyon, 15(2), 47-54.
  • Frayman KB, Kazmerski TM, Sawyer SM. A systematic review of the prevalence and impact of urinary incontinence in cystic fibrosis. Respirology. 2018 Jan;23(1):46-54. doi: 10.1111/resp.13125. Epub 2017 Jul 18. PubMed 28718995 ↗
  • Heron J, Grzeda MT, von Gontard A, Wright A, Joinson C. Trajectories of urinary incontinence in childhood and bladder and bowel symptoms in adolescence: prospective cohort study. BMJ Open. 2017 Mar 14;7(3):e014238. doi: 10.1136/bmjopen-2016-014238. PubMed 28292756 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Mar 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2025
First posted
May 22, 2025
StartActual
Sep 15, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 3, 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06984679
Lead sponsor
Izmir Democracy University
Responsible party
Gulsah Bargi (Principal Investigator, Izmir Democracy University) — Principal investigator
First posted
May 22, 2025
Start date
Sep 15, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 3, 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

Gülşah Barğı, Assoc Prof
Contact
gulsahbargi35@gmail.com
+90 232 299 0739
Yağmur Külekçi, PT
Contact
yagmurkulekci1401@gmail.com
+90 533 661 4001
Gülşah Barğı, Assoc Prof
study director · Izmir Democracy University
Yağmur Külekçi, PT
principal investigator · Izmir Democracy University
Gökçen Kartal Öztürk, Assoc Prof
principal investigator · Ege University
Ece Ocak, Dr
principal investigator · Izmir City Hospital
Kübra Özkaya, Dr
principal investigator · Ege University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion